14.2.2025 13:57:58 CET | Aqua Bio Technology ASA | Additional regulated
information required to be disclosed under the laws of a member state
Aqua Bio Technology ASA ('ABT' or 'the Company') announced on February 12, 2025,
that the negative result for 2024 is primarily due to significant impairments of
goodwill related to the bankruptcy of its subsidiary, Skinteam Norge AS, as well
as operating losses in two of the Group's subsidiaries.
ABT emphasizes that the majority of the operating losses in two subsidiaries in
2024 are due to significant and extraordinary impairments.
- The impairments position the group better to deliver shareholder value in the
future,' says Fredrik William Henriksen.
DISCLOSURE REGULATION
This information is subject of the disclosure requirements pursuant to section
of 5-12 of the Norwegian Securities Trading Act.
CONTACTS
* Fredrik Henriksen, CEO, Aqua Bio Technology ASA, +47 90 02 00 78,
fredrik.henriksen@aquabiotech.no
* Geir Udnæs, CFO, Aqua Bio Technology ASA, +47 91 36 18 93,
geir.udnaes@aquabiotech.no
ABOUT AQUA BIO TECHNOLOGY ASA
Aqua Bio Technology ASA (ABT) is a distribution group in skincare and nonfood.
The group has distribution towards B2C, B2B, B2B2, and freight, customs, and
logistics services. The group also develops sustainable biotechnology for use in
skincare products. Aqua Bio Technology is listed on Euronext Expand.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/18423779/5634/Download%20announce
ment%20as%20PDF.pdf
Recent Comments